These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38787931)

  • 21. Intravenous Cellular Therapies for Acute Ischemic Stroke.
    Mays RW; Savitz SI
    Stroke; 2018 May; 49(5):1058-1065. PubMed ID: 29669867
    [No Abstract]   [Full Text] [Related]  

  • 22. ACC1 (Acetyl Coenzyme A Carboxylase 1) Is a Potential Immune Modulatory Target of Cerebral Ischemic Stroke.
    Wang X; Zhou Y; Tang D; Zhu Z; Li Y; Huang T; Müller R; Yu W; Li P
    Stroke; 2019 Jul; 50(7):1869-1878. PubMed ID: 31177975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation?
    Xia Y; Cai W; Thomson AW; Hu X
    Transl Stroke Res; 2016 Oct; 7(5):415-9. PubMed ID: 27307291
    [No Abstract]   [Full Text] [Related]  

  • 24. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia.
    Xie L; Sun F; Wang J; Mao X; Xie L; Yang SH; Su DM; Simpkins JW; Greenberg DA; Jin K
    J Immunol; 2014 Jun; 192(12):6009-19. PubMed ID: 24829408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different treatment settings of Granulocyte-Colony Stimulating Factor and their impact on T cell-specific immune response in experimental stroke.
    Dietel B; Cicha I; Achenbach S; Kollmar R; Garlichs C; Tauchi M
    Immunol Lett; 2014; 158(1-2):95-100. PubMed ID: 24333341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive regulatory T-cell therapy protects against cerebral ischemia.
    Li P; Gan Y; Sun BL; Zhang F; Lu B; Gao Y; Liang W; Thomson AW; Chen J; Hu X
    Ann Neurol; 2013 Sep; 74(3):458-71. PubMed ID: 23674483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between the induction of inflammatory processes and infectious diseases in patients with ischemic stroke.
    Cieślak M; Wojtczak A; Cieślak M
    Acta Biochim Pol; 2013; 60(3):345-9. PubMed ID: 24046817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice.
    Na SY; Mracsko E; Liesz A; Hünig T; Veltkamp R
    Stroke; 2015 Jan; 46(1):212-20. PubMed ID: 25378432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Involvement and Therapy Target of Immune Cells After Ischemic Stroke.
    Jian Z; Liu R; Zhu X; Smerin D; Zhong Y; Gu L; Fang W; Xiong X
    Front Immunol; 2019; 10():2167. PubMed ID: 31572378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glia-immune interactions post-ischemic stroke and potential therapies.
    Hersh J; Yang SH
    Exp Biol Med (Maywood); 2018 Dec; 243(17-18):1302-1312. PubMed ID: 30537868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-2mAb reduces demyelination after focal cerebral ischemia by suppressing CD8
    Zhou YX; Wang X; Tang D; Li Y; Jiao YF; Gan Y; Hu XM; Yang LQ; Yu WF; Stetler RA; Li PY; Wen DX
    CNS Neurosci Ther; 2019 Apr; 25(4):532-543. PubMed ID: 30444079
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Zhang H; Xia Y; Ye Q; Yu F; Zhu W; Li P; Wei Z; Yang Y; Shi Y; Thomson AW; Chen J; Hu X
    J Neurosci; 2018 Nov; 38(47):10168-10179. PubMed ID: 30291203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administering Thrombolysis for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants: To Treat or How to Treat.
    Seiffge DJ; Wilson D; Wu TY
    JAMA Neurol; 2021 May; 78(5):515-516. PubMed ID: 33720313
    [No Abstract]   [Full Text] [Related]  

  • 34. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia.
    Brait VH; Arumugam TV; Drummond GR; Sobey CG
    J Cereb Blood Flow Metab; 2012 Apr; 32(4):598-611. PubMed ID: 22293986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute management of childhood stroke.
    Chung MG; Pabst L
    Curr Opin Pediatr; 2023 Dec; 35(6):648-655. PubMed ID: 37800414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial.
    Smith CJ; Hulme S; Vail A; Heal C; Parry-Jones AR; Scarth S; Hopkins K; Hoadley M; Allan SM; Rothwell NJ; Hopkins SJ; Tyrrell PJ
    Stroke; 2018 May; 49(5):1210-1216. PubMed ID: 29567761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells.
    Jin R; Yang G; Li G
    J Leukoc Biol; 2010 May; 87(5):779-89. PubMed ID: 20130219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-1 receptor antagonist in animal models of stroke: a fair summing up?
    Parry-Jones A; Boutin H; Denes A; McColl B; Hopkins S; Allan S; Tyrrell P
    J Stroke Cerebrovasc Dis; 2010; 19(6):512-3. PubMed ID: 20621515
    [No Abstract]   [Full Text] [Related]  

  • 39. Regulatory T cells in ischemic stroke.
    Wang H; Wang Z; Wu Q; Yuan Y; Cao W; Zhang X
    CNS Neurosci Ther; 2021 Jun; 27(6):643-651. PubMed ID: 33470530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dampened Immune Response After Early Recurrence of Ischemic Stroke.
    Semerano A; Roveri L; Martino G; Filippi M; Bacigaluppi M
    J Am Coll Cardiol; 2020 Sep; 76(11):1385-1387. PubMed ID: 32912450
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.